Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium-dependent organic cation transporter 2 (OCTN2)
- Target
- OCTN2
- Molecular classification
- Transporter, Solute carrier family (specifically, member 22A5), Sodium-dependent organic cation transporter
01
Overview
The sodium-dependent organic cation transporter 2 (OCTN2), encoded by the SLC22A5 gene, is a multi-transmembrane protein (12 transmembrane domains) expressed widely throughout the body, including the kidney, muscle, heart, and brain. Its primary function is to facilitate the cellular uptake and systemic homeostasis of carnitine, an essential molecule for the transport of long-chain fatty acids into mitochondria for β-oxidation. Genetic defects in OCTN2 lead to carnitine transporter deficiency, characterized by severe metabolic disturbances. OCTN2 is a validated therapeutic target for metabolic disorders and is of interest for the development of novel pharmacological chaperones intended to rescue misfolded or mislocalized transporter variants.
- Other names
- SLC22A5Carnitine transporter 1 (CT1)OCTN2
02
Mechanism of action
Drugs (e.g., L-carnitine supplementation) act by compensating for defective transport and restoring normal carnitine-dependent metabolism. Inhibitors (acylcarnitines, some drugs) may block carnitine uptake by competitive inhibition.
03
Biological functions
Carnitine uptake/transportFatty acid oxidationEnergy metabolismMaintenance of systemic carnitine levels
04
Disease associations
Carnitine transporter deficiency (primary carnitine deficiency; CTD)Metabolic disorders of fatty acid oxidationPotential roles in cardiovascular disease and neurometabolic conditions (due to energy homeostasis)
05
Safety considerations
Risk of carnitine deficiency with transporter mutations leading to hypoketotic hypoglycemia, skeletal and cardiac myopathy, and metabolic crisesNo major safety concerns associated with pharmacological targeting, but careful monitoring required during L-carnitine therapy
06
Interacting drugs
L-carnitine (supplement/replacement therapy)
2 more in the full profile.
07
Biomarkers
Plasma carnitine concentrationMutation analysis of SLC22A5 gene for diagnosis
Beyond the preview
Go deeper on Sodium-dependent organic cation transporter 2 (OCTN2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sodium-dependent organic cation transporter 2 (OCTN2).